Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,664.80
(
-0.55%
)
Dow Jones
46,225.15
(
0.00%
)
Brent Oil
109.68
(
2.90%
)
Bitcoin
69,890.92
(
-1.89%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jbog

Send PM Follow Ignore
Followers 64
Posts 11870
Boards Moderated 0
Alias Born 07/16/2006

jbog

Re: DewDiligence post# 158915

Saturday, 03/30/2013 10:08:56 PM

Saturday, March 30, 2013 10:08:56 PM

Post# of 257257
With Biogen pricing Tecfidera ($55k/yr) right in the middle of Gilenya ($60K/yr) and Aubagio ($48.0k/yr.

After a year or so if Tecfidera's side effect profile is within expectations it'll take the dominant position in MS care.

The injectables, Copaxone, Rebif and Avonex will start to wither away once the safety parameters are met.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now